HRP20170548T1 - Anti-fgf23 protutijelo i farmaceutski sastav koji ga sadrži - Google Patents
Anti-fgf23 protutijelo i farmaceutski sastav koji ga sadrži Download PDFInfo
- Publication number
- HRP20170548T1 HRP20170548T1 HRP20170548TT HRP20170548T HRP20170548T1 HR P20170548 T1 HRP20170548 T1 HR P20170548T1 HR P20170548T T HRP20170548T T HR P20170548TT HR P20170548 T HRP20170548 T HR P20170548T HR P20170548 T1 HRP20170548 T1 HR P20170548T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- nucleotide position
- amino acid
- variable region
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 239000002773 nucleotide Substances 0.000 claims 20
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 101100281001 Homo sapiens FGF23 gene Proteins 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 208000027361 mineral metabolism disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000028060 Albright disease Diseases 0.000 claims 1
- 208000004434 Calcinosis Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 208000013038 Hypocalcemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 201000001853 McCune-Albright syndrome Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000000023 Osteosclerosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 claims 1
- 208000031878 X-linked hypophosphatemia Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000003674 autosomal dominant hypophosphatemic rickets Diseases 0.000 claims 1
- 208000037691 autosomal recessive 1 hypophosphatemic rickets Diseases 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010103 fibrous dysplasia Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000000705 hypocalcaemia Effects 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
Claims (13)
1. Protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela prema ljudskom FGF23,
a) pri čemu protutijelo na ljudski FGF23 ili na funkcionalni fragment navedenog protutijela obuhvaća varijabilnu regiju teškog lanca koja ima komplementarnu determinirajuću regiju (CDR) 1 prikazanu aminokiselinskim slijedom SEQ ID NO:40, CDR2 prikazanu aminokiselinskim slijedom SEQ ID NO:41 i CDR3 prikazanu aminokiselinskim slijedom SEQ ID NO:42 i varijabilnu regiju lakog lanca koja ima komplementarnu determinirajuću regiju (CDR) 1 prikazanu aminokiselinskim slijedom SEQ ID NO:43, CDR2 prikazanu aminokiselinskim slijedom SEQ ID NO:44 i CDR3 prikazanu aminokiselinskim slijedom SEQ ID NO:45, ili
2. pri čemu je protutijelo na ljudski FGF23 proizvedeno od hibridome FERM BP-10772, ili
3. protutijelo ili fragment koje obuhvaća isti slijed aminokiselina kao varijabilna regija teškog lanca i varijabilna regija lakog lanca protutijela proizvedenog od hibridome FERM BP-10772.
2. Funkcionalni fragment iz patentnog zahtjeva 1, pri čemu je navedeni funkcionalni fragment fragment peptida izabran iz grupe koja se sastoji od Fab, Fab', F(ab')2, disulfidom stabilizirane Fv (dsFv), dimerizirane V regije (dijatijelo), jednolančanog Fv (scFv) i CDR.
3. Protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela iz patentnog zahtjeva 1 ili 2, obuhvaća teški lanac ili laki lanac koji ima aminokiselinski slijed u kojem je obrisana, zamijenjena ili dodana jedna ili nekoliko aminokiselina.
4. Protutijelo na ljudski FGF23 iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je razred protutijela izabran iz grupe koja se sastoji od IgG, IgA, IgE i IgM.
5. Protutijelo na ljudski FGF23 iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je podrazred IgG protutijela odabran iz grupe koja se sastoji od IgG1, IgG2, IgG3 i IgG4.
6. Farmaceutski sastav, kao aktivni sastojak sadrži protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela iz bilo kojeg od patentnih zahtjeva 1-5.
7. Farmaceutski sastav za uporabu u motodi sprječavanja ili liječenja bolesti koja je povezana s poremećajima metabolizma minerala, navedeni sastav kao aktivni sastojak sadrži protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela iz bilo kojeg od patentnih zahtjeva 1-5, pri čemu je bolest koja je povezana s poremećajima metabolizma minerala odabrana iz grupe koja se sastoji od neoplastične osteomalacije, ADHR, XLH, fibrozne displazije, sindroma McCune-Albright i autosomne recesivne hipofosfatemije.
8. Farmaceutski sastav za uporabu u metodi sprječavanja ili liječenja bolesti odabrane iz grupe koja se sastoji od osteoporoze, rahitisa, hiperkalcemije, hipokalcemije, heterotrofne kalcifikacije, osteoskleroze, Pagetove bolesti, hiperparatireoidizma, hipoparatireoidizma i pruritusa, navedeni sastav kao aktivni sastojak sadrži protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela iz bilo kojeg od patentnih zahtjeva 1-5.
9. Hibridoma pohranjena s pristupnim brojem FERM BP-10772.
10. Nukleinska kiselina koja kodira varijabilnu regiju teškog lanca i varijabilnu regiju lakog lanca obuhvaća slijed od nukleotida na poziciji 58 iz SEQ ID NO:11 do nukleotida na poziciji 408 iz SEQ ID NO:11 i slijed od nukleotida na poziciji 67 iz SEQ ID NO:13 do nukleotida na poziciji 384 iz SEQ ID NO:13.
11. Vektor koji sadrži nukleinsku kiselinu iz patentnog zahtjeva 10.
12. Stanica domaćin koja sadrži vektor iz patentnog zahtjeva 11.
13. Metoda za proizvodnju protutijela na ljudski FGF23 ili funkcionalni fragment navedenog protutijela, obuhvaća korak kultiviranje stanice domaćina,
a) stanica domaćin sadrži nukleinsku kiselinu koja kodira aminokiselinski slijed varijabilne regije teškog lanca kodirane slijedom nukleotida od nukleotida na poziciji 58 iz SEQ ID NO:11 do nukleotida na poziciji 408 iz SEQ ID NO:11 i nukleinsku kiselinu koja kodira aminokiselinski slijed varijabilne regije lakog lanca kodirane slijedom nukleotida od nukleotida na poziciji 67 iz SEQ ID NO:13 do nukleotida na poziciji 384 iz SEQ ID NO:13, ili
b) stanica domaćin sadrži nukleinsku kiselinu iz patentnog zahtjeva 10, ili
c) stanica domaćin sadrži vektor koji sadrži nukleinsku kiselinu koja kodira aminokiselinski slijed varijabilne regije teškog lanca kodirane slijedom nukleotida od nukleotida na poziciji 58 iz SEQ ID NO:11 do nukleotida na poziciji 408 iz SEQ ID NO:11 i vektor koji sadrži nukleinsku kiselinu koja kodira aminokiselinski slijed varijabilne regije lakog lanca kodirane slijedom nukleotida od nukleotida na poziciji 67 iz SEQ ID NO:13 do nukleotida na poziciji 384 iz SEQ ID NO:13, ili
d) stanica domaćin sadrži vektor koji sadrži nukleinsku kiselinu koja kodira aminokiselinski slijed varijabilne regije teškog lanca i varijabilne regije lakog lanca kodirane redom slijedom od nukleotida na poziciji 58 iz SEQ ID NO:11 do nukleotida na poziciji 408 iz SEQ ID NO:11 i slijed od nukleotida na poziciji 67 iz SEQ ID NO:13 do nukleotida na poziciji 384 iz SEQ ID NO:13.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007034018 | 2007-02-14 | ||
| EP12170984.4A EP2502996B1 (en) | 2007-02-14 | 2008-02-14 | Anti-FGF23 antibody and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170548T1 true HRP20170548T1 (hr) | 2017-08-25 |
Family
ID=39690189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170548TT HRP20170548T1 (hr) | 2007-02-14 | 2017-04-04 | Anti-fgf23 protutijelo i farmaceutski sastav koji ga sadrži |
| HRP20201266TT HRP20201266T1 (hr) | 2007-02-14 | 2020-08-11 | Anti fg23 antitijelo i farmaceutski pripravak koji sadrži isto |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201266TT HRP20201266T1 (hr) | 2007-02-14 | 2020-08-11 | Anti fg23 antitijelo i farmaceutski pripravak koji sadrži isto |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7883705B2 (hr) |
| EP (3) | EP3181691B1 (hr) |
| JP (1) | JP4800396B2 (hr) |
| KR (1) | KR101462291B1 (hr) |
| CN (2) | CN102702355B (hr) |
| AU (1) | AU2008215346B2 (hr) |
| CA (1) | CA2677782C (hr) |
| CY (3) | CY1118835T1 (hr) |
| DK (3) | DK2502996T3 (hr) |
| ES (3) | ES2530670T3 (hr) |
| FR (1) | FR18C1032I2 (hr) |
| HK (2) | HK1140228A1 (hr) |
| HR (2) | HRP20170548T1 (hr) |
| HU (3) | HUE050517T2 (hr) |
| LT (3) | LT2502996T (hr) |
| LU (2) | LUC00081I2 (hr) |
| NL (1) | NL300945I2 (hr) |
| NO (1) | NO2018025I1 (hr) |
| PL (3) | PL2128253T3 (hr) |
| PT (3) | PT2128253E (hr) |
| SI (2) | SI3181691T1 (hr) |
| TW (1) | TWI422593B (hr) |
| WO (1) | WO2008099969A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002014504A1 (fr) * | 2000-08-11 | 2002-02-21 | Kirin Beer Kabushiki Kaisha | Polypeptides de regulation du metabolisme de l'acide phosphorique, du metabolisme du calcium, du metabolisme de la calcification et de la vitamine d et des adn codant pour de tels polypeptides |
| EP1466925B1 (en) * | 2001-12-28 | 2009-09-02 | Kyowa Hakko Kirin Co., Ltd. | Antibodies against fibroblast growth factor 23 |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| WO2012050673A1 (en) | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| US20140294820A1 (en) | 2011-06-24 | 2014-10-02 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| EP3151859B1 (en) * | 2014-06-09 | 2020-11-25 | Ultragenyx Pharmaceutical Inc. | The effective and efficient control of serum phosphate for optimal bone formation |
| WO2018069232A1 (en) | 2016-10-10 | 2018-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of having cardiac hypertrophy |
| WO2018181935A1 (ja) | 2017-03-30 | 2018-10-04 | シスメックス株式会社 | 抗ＡｐｏＡ１抗体 |
| WO2020205523A1 (en) * | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anti fgf23 antibody |
| WO2024034638A1 (ja) * | 2022-08-10 | 2024-02-15 | 協和キリン株式会社 | 抗ｆｇｆ２３抗体又は該抗体断片 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
| WO1985003934A1 (en) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61178926U (hr) | 1985-04-23 | 1986-11-08 | ||
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
| JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5958879A (en) | 1989-10-12 | 1999-09-28 | Ohio University/Edison Biotechnology Institute | Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO2000073454A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| AU765349B2 (en) | 1998-05-18 | 2003-09-18 | University College London | A novel polypeptide hormone phosphatonin |
| TWI255853B (en) | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
| AU3924300A (en) | 1999-04-02 | 2000-10-23 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
| US6596849B1 (en) | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
| EP1661996A1 (en) | 1999-12-01 | 2006-05-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2003516150A (ja) | 1999-12-08 | 2003-05-13 | ジェンセット | 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ |
| AU2759201A (en) | 2000-01-05 | 2001-07-16 | Zymogenetics Inc. | Novel fgf homolog zfgf12 |
| EP1255771A4 (en) | 2000-02-14 | 2004-09-29 | Smithkline Beecham Corp | NEW COMPOUNDS |
| US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| MXPA02007619A (es) | 2000-02-15 | 2002-12-13 | Amgen Inc | Moleculas de factor 23 de crecimiento de fibroblastos y su uso. |
| US20030105302A1 (en) | 2000-03-08 | 2003-06-05 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
| US20020082205A1 (en) | 2000-03-08 | 2002-06-27 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
| US7223563B2 (en) | 2000-07-19 | 2007-05-29 | Advanced Research And Technology Institute | Fibroblast growth factor (FGF23) nucleic acids |
| WO2002014504A1 (fr) | 2000-08-11 | 2002-02-21 | Kirin Beer Kabushiki Kaisha | Polypeptides de regulation du metabolisme de l'acide phosphorique, du metabolisme du calcium, du metabolisme de la calcification et de la vitamine d et des adn codant pour de tels polypeptides |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| WO2002076467A1 (en) | 2001-03-22 | 2002-10-03 | Genzyme Corporation | Compositions and methods to regulate bone and mineral metabolism |
| CN1602355A (zh) | 2001-04-26 | 2005-03-30 | 杰诺瓦有限公司 | 与人成纤维细胞生长因子有关的组合物 |
| ATE374214T1 (de) * | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| EP1466925B1 (en) | 2001-12-28 | 2009-09-02 | Kyowa Hakko Kirin Co., Ltd. | Antibodies against fibroblast growth factor 23 |
| US7094551B2 (en) | 2002-09-17 | 2006-08-22 | Zahradnik Richard J | Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23 |
| US20070036734A1 (en) * | 2003-03-17 | 2007-02-15 | Kirin Beer Kabushiki Kaisha | Therapeutic agent for periodontal disease |
| AU2005250499B2 (en) * | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| RS51326B (sr) * | 2004-08-05 | 2010-12-31 | Genentech Inc. | Humanizovani anti-cmet antagonisti |
| AU2005280975B2 (en) * | 2004-09-06 | 2009-06-18 | Kyowa Hakko Kirin Co., Ltd. | Anti-A33 antibody |
| US20090151011A1 (en) | 2005-01-21 | 2009-06-11 | Kirin Pharma Kabushiki Kaisha | Chimeric Non-Human Animal and Use Thereof |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| US20100062984A1 (en) * | 2007-01-25 | 2010-03-11 | Rajiv Kumar | Fgf-23 polypeptides |
| US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
-
2008
- 2008-02-13 US US12/030,593 patent/US7883705B2/en active Active
- 2008-02-14 EP EP17152168.5A patent/EP3181691B1/en active Active
- 2008-02-14 ES ES08711707T patent/ES2530670T3/es active Active
- 2008-02-14 WO PCT/JP2008/052918 patent/WO2008099969A1/ja active Application Filing
- 2008-02-14 PT PT87117073T patent/PT2128253E/pt unknown
- 2008-02-14 DK DK12170984.4T patent/DK2502996T3/en active
- 2008-02-14 CN CN201210161119.8A patent/CN102702355B/zh active Active
- 2008-02-14 DK DK08711707.3T patent/DK2128253T3/en active
- 2008-02-14 PL PL08711707T patent/PL2128253T3/pl unknown
- 2008-02-14 LU LU00081C patent/LUC00081I2/en unknown
- 2008-02-14 EP EP12170984.4A patent/EP2502996B1/en active Active
- 2008-02-14 SI SI200832131T patent/SI3181691T1/sl unknown
- 2008-02-14 PL PL12170984T patent/PL2502996T3/pl unknown
- 2008-02-14 EP EP08711707.3A patent/EP2128253B1/en active Active
- 2008-02-14 SI SI200831797T patent/SI2502996T1/sl unknown
- 2008-02-14 PL PL17152168T patent/PL3181691T3/pl unknown
- 2008-02-14 ES ES17152168T patent/ES2811318T3/es active Active
- 2008-02-14 LT LTEP12170984.4T patent/LT2502996T/lt unknown
- 2008-02-14 HU HUE17152168A patent/HUE050517T2/hu unknown
- 2008-02-14 TW TW097105234A patent/TWI422593B/zh active
- 2008-02-14 PT PT171521685T patent/PT3181691T/pt unknown
- 2008-02-14 HU HUE12170984A patent/HUE031728T2/en unknown
- 2008-02-14 CN CN2008800048145A patent/CN101652476B/zh active Active
- 2008-02-14 JP JP2008558165A patent/JP4800396B2/ja active Active
- 2008-02-14 LT LTEP17152168.5T patent/LT3181691T/lt unknown
- 2008-02-14 KR KR1020097019085A patent/KR101462291B1/ko active Protection Beyond IP Right Term
- 2008-02-14 ES ES12170984T patent/ES2625823T3/es active Active
- 2008-02-14 LU LU00082C patent/LUC00082I2/en unknown
- 2008-02-14 AU AU2008215346A patent/AU2008215346B2/en active Active
- 2008-02-14 CA CA2677782A patent/CA2677782C/en active Active
- 2008-02-14 PT PT121709844T patent/PT2502996T/pt unknown
- 2008-02-14 DK DK17152168.5T patent/DK3181691T3/da active
-
2010
- 2010-06-28 HK HK10106310.8A patent/HK1140228A1/xx unknown
-
2011
- 2011-02-02 US US13/019,557 patent/US9290569B2/en active Active
-
2013
- 2013-01-04 HK HK13100123.5A patent/HK1172917A1/xx unknown
-
2016
- 2016-02-10 US US15/040,103 patent/US10202446B2/en active Active
-
2017
- 2017-04-04 HR HRP20170548TT patent/HRP20170548T1/hr unknown
- 2017-04-19 CY CY20171100446T patent/CY1118835T1/el unknown
-
2018
- 2018-07-27 NL NL300945C patent/NL300945I2/en unknown
- 2018-07-27 FR FR18C1032C patent/FR18C1032I2/fr active Active
- 2018-08-01 LT LTPA2018508C patent/LTC2502996I2/lt unknown
- 2018-08-02 HU HUS1800034C patent/HUS1800034I1/hu unknown
- 2018-08-07 CY CY2018021C patent/CY2018021I2/el unknown
- 2018-08-09 NO NO2018025C patent/NO2018025I1/no unknown
- 2018-12-18 US US16/223,930 patent/US20190106485A1/en not_active Abandoned
-
2020
- 2020-08-03 CY CY20201100713T patent/CY1123240T1/el unknown
- 2020-08-11 HR HRP20201266TT patent/HRP20201266T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170548T1 (hr) | Anti-fgf23 protutijelo i farmaceutski sastav koji ga sadrži | |
| ES2605945T3 (es) | Anticuerpos de unión a Tweak | |
| HRP20201438T1 (hr) | Metoda inhibiranja resorpcije kosti | |
| US20190153086A1 (en) | Heterodimeric Immunoglobulins | |
| DK2970980T3 (en) | METHODS FOR MANAGING C-TERMINAL LYSIN, GALACTOSE AND SIALINIC ACID CONTENTS IN RECOMBINANT PROTEINS | |
| JP6210966B2 (ja) | 抗Ｓｉｇｌｅｃ−１５抗体 | |
| HRP20201503T1 (hr) | MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79 | |
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| JP2020517249A5 (hr) | ||
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| HRP20230344T1 (hr) | Protutijela protiv sortilina i postupci njihove upotrebe | |
| HRP20160082T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| JP2010539190A5 (hr) | ||
| JP2013535952A5 (hr) | ||
| WO2013147213A1 (ja) | ＣＤＲ改変抗Ｓｉｇｌｅｃ－１５抗体 | |
| RU2010106639A (ru) | Антитело, направленное на белок siglec-15, связанный с остеокластами | |
| EP2146745A2 (en) | Novel compounds | |
| CN103732622A (zh) | 抗神经生长因子抗体及其制备和使用方法 | |
| CA2483848A1 (en) | Antibody against human insulin-like growth factor | |
| JP2009523154A5 (hr) | ||
| HRP20210892T1 (hr) | Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv | |
| RU2014143770A (ru) | Новое антитело против siglec-15 | |
| CA2400929A1 (en) | Antagonistic selective binding agents of osteoprotegerin binding protein | |
| HRP20201366T1 (hr) | Metoda liječenja osteoporoze | |
| WO2021013142A1 (zh) | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 |